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Abstract  1	
The aim of this study was to evaluate the use of biological serum markers, 2	
available routinely in most hospital clinical laboratories, in predicting 3	
successful outcome of expectant management in women presenting with a 4	
missed miscarriage. This is a single centre observational prospective study 5	
over a 16 month-period. Among the 490 women who consented to the study 6	
protocol, 83 presented with missed miscarriage during the first trimester of 7	
pregnancy and opted for expectant management. The mean gestation sac 8	
diameter (MSD) and the volume of the gestation sac were recorded during the 9	
ultrasound examination. Maternal serum samples were obtained in each case 10	
and assayed for human chorionic gonadotrophin, progesterone, pregnancy 11	
associated plasma protein A (PAPP-A) and high-sensitivity C-reactive protein 12	
using commercial assays. When examined individually, maternal age 13	
(p=0.01), progesterone (p=0.03) and PAPP-A (p=0.02) were all significantly 14	
associated with successful expectant management. Increased maternal age 15	
was associated with an increased chance of success with the odds of success 16	
increased by around 75% for a 5-year increase in age.  Higher values of both 17	
progesterone and PAPP-A were associated with a reduced chance of 18	
successful management. Low maternal serum progesterone level was the 19	
strongest parameter associated with a successful spontaneous completion of 20	
miscarriage.  21	
 22	
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Introduction 1	
Between 12-24% of women with a missed menstrual period and positive urine 2	
pregnancy test will present with a miscarriage or early pregnancy failure 3	
(Nybo Andersen et al., 2000). It is estimated that around 125,000 4	
miscarriages occur annually in the United Kingdom (Knez et al., 2014). 5	
Miscarriages result in 42,000 hospital admissions and are considered the 6	
most common clinical complication of human pregnancy. Access to 7	
transvaginal ultrasound by trained staff has considerably improved the 8	
management of early pregnancy loss (Jurkovic et al., 2013).  9	
 A missed miscarriage corresponds to an early embryonic demise and 10	
refers to the early stage in the natural history of a miscarriage. Missed 11	
miscarriages have been referred to in the medical literature as an empty sac 12	
(anembryonic), blighted ovum, delayed or silent miscarriage. A missed 13	
miscarriage is diagnosed on ultrasound when there is no embryo within a 14	
gestational sac or when there is a visible embryo	 with no cardiac activity 15	
(Jurkovic et al.,2013; Knez et al., 2014). A missed miscarriage must be 16	
differentiated from an incomplete miscarriage, which is defined by the 17	
presence of retained intra-uterine products of conception without a well-18	
defined gestation sac. The ultrasound diagnosis of incomplete miscarriage 19	
can be difficult and there is no consensus on the best diagnostic criteria 20	
(Jurkovic et al., 2013).  21	
 Surgical management under general anesthesia used to be the only 22	
option for women presenting with a missed miscarriage on the basis that it 23	
decreases the risk of hemorrhage and subsequent gynecological infection. 24	
Over the past 2 decades, the management of miscarriage has radically 25	
	 4	
changed and has moved towards individualized treatment and patient choice 1	
between expectant, medical, and semi-elective surgical treatment. Improved 2	
access to specialized Early Pregnancy Units and increasing awareness 3	
amongst women of their choices in the management of early pregnancy 4	
complications have led to an increasing demand for more conservative 5	
management of early miscarriage (Jurkovic et al., 2013).  6	
Expectant management is now regularly chosen by women presenting 7	
with first trimester missed and incomplete miscarriage to avoid a surgical 8	
evacuation. In one observational study, it was found that 70% of women opted 9	
to wait for the pregnancy to resolve spontaneously (Luise et al., 2002). 10	
Medical management by means of prostaglandin has also become an option, 11	
chosen as the primary treatment option by 20-30% of women (Shankar et al., 12	
2007).  A recent meta-analysis of randomised trials comparing expectant care 13	
and surgical treatment has shown that the risks of infection and psychological 14	
outcomes are similar for both groups and that the costs are lower for 15	
expectant management (Nanda et al., 2012). However, expectant 16	
management is associated with a higher risk of incomplete miscarriage, need 17	
for unplanned or additional surgical evacuation of the uterus, bleeding and 18	
need for transfusion (NICE, 2012). The main issue with expectant 19	
management has been the lack of ultrasound and/or biological criteria that 20	
can accurately predict the likelihood of a successful spontaneous completion 21	
of miscarriage (Elson et al., 2005).  22	
Several biochemical markers and algorithms have been trialed over the 23	
last decade in an attempt to guide clinicians and women in the decision-24	
making process with varying success due mainly to small numbers, different 25	
	 5	
populations studied and different methodologies used. Unlike, human 1	
chorionic gonadotrophin (hCG) and progesterone assays, the assays for new 2	
proteins are not available routinely in most hospital clinical laboratories. 3	
Maternal serum pregnancy-associated protein A (PAPP-A) is now widely used 4	
to predict adverse pregnancy outcomes (Wells et al., 2015; Yliniemi et al., 5	
2015) and high-sensitivity C-reactive (hsCRP) protein is routinely used in 6	
cardiovascular disease risk stratification and management (Kalogeropoulos et 7	
al., 2014).  8	
 The aim of this study was to evaluate the role of biochemical markers 9	
available in routine clinical laboratories in predicting successful expectant 10	
management of first trimester missed miscarriage and incomplete 11	
miscarriage. 12	
 13	
Materials and methods 14	
The early pregnancy assessment unit (EPAU) at University College London 15	
Hospital (UCLH) is part of the Emergency Gynaecological service, which 16	
provides daily ultrasound and biological investigations to all women 17	
presenting with pelvic pain and/or bleeding in early pregnancy. All pregnant 18	
women presenting with bleeding and or pain have routine blood investigations 19	
including blood group and full blood count. Women with suspected ectopic 20	
pregnancy are routinely tested for hCG serum and progesterone levels. In 21	
addition, blood samples were collected as part of a prospective cohort study 22	
on the diagnosis and management of early pregnancy disorders. Maternal 23	
serum and plasma were separated and frozen at -80C° until analysis. 24	
	 6	
 The patients for this study were recruited prospectively from a cohort of 1	
consecutive 523 pregnant women attending the EPAU over a 16 month-2	
period. There were 490 women who consented to the study protocol, 3	
including women diagnosed with threatened (n= 111), complete (n= 52), 4	
incomplete (n= 22) or missed miscarriage (n= 99), women with an ectopic 5	
pregnancy (n= 54) or a pregnancy of unknown location (n= 67) and women 6	
with an uncomplicated singleton pregnancy referred for a reassurance scan 7	
because of a previous history of pregnancy loss or pelvic pain (n= 85).   8	
Women with multiple pregnancies, women with pregnancies resulting 9	
from assisted reproductive technologies and women who were on 10	
supplemental hormonal treatment were excluded from the study group. 11	
Demographic data including maternal age, ethnicity, parity, cigarette smoke 12	
exposure, age and body mass index (BMI) were collected from questionnaires 13	
completed at the time of the first appointment. Pregnancy outcome 14	
information was collected from the medical case notes and hospital electronic 15	
patient records. The study was approved by the Joint UCL/UCLH Committees 16	
on the Ethics of Human Research on 3rd December 2007 (Reference Number: 17	
07/Q0512/41). All women received information about the study and written 18	
consent was obtained prior to the ultrasound examination. 19	
 The study group included women diagnosed with a missed miscarriage 20	
during the first trimester of pregnancy and opting for expectant management. 21	
The diagnosis of missed miscarriage was defined as a gestational sac size 22	
>20 mm in diameter with no evidence of an embryo or yolk sac; or as fetal 23	
crown-rump length (CRL) >6 mm with no fetal heart rate, or in case of no 24	
evidence of fetal development and/or no fetal heart activity during a follow-up 25	
	 7	
scan performed ≥7 days since the initial examination (The association of Early 1	
Pregnancy Units. AEPU organisational, clinical and supportive guidelines, 2	
2007; http://www.early pregnancy.org.uk). 3	
All examinations were carried out by an experienced operator using a 4	
high-resolution transvaginal probe (Voluson 730 and E8 expert, GE, USA). 5	
Pregnancies were dated according to the last menstrual period (LMP). Other 6	
measurements obtained during the scan and collected for the study were the 7	
mean gestation sac diameter (MSD) and the volume of the gestation sac.  8	
 Women were then followed-up in line with the EPAU guidelines for 9	
expectant management of missed miscarriage. Their pain and bleeding levels 10	
(none, mild, moderate and heavy) were recorded at the time of the first 11	
consultation. Women were asked to attend the unit 7 days post-diagnosis for 12	
a urinary pregnancy test, and a subsequent ultrasound examination, was 13	
performed, if the pregnancy test was positive or if women experienced 14	
continuous vaginal bleeding. Follow-up was completed if the pregnancy test 15	
was negative and the bleeding had settled (successful outcome of expectant 16	
management). Women who opted for surgical management either due to 17	
worsening symptoms or personal choice (e.g. prolonged follow-up) were 18	
included in the failed outcome group. In all cases, the pregnancy outcome 19	
was confirmed by telephone follow-up or through the UCLH maternity 20	
database. Only cases with a full set of data including demographic 21	
information, serum biomarkers results and clinical outcomes were included in 22	
the final analysis. 23	
 24	
	 8	
Bioassays 1	
All maternal serum samples were assayed for hCG, progesterone, PAPP-A 2	
and hsCRP using commercial assays. Maternal serum progesterone and hCG 3	
assays were performed on a Modular E170 Analyzer (Roche Diagnostics, 4	
Vilvoorde, Belgium) with an electrochemiluminescence competitive methods.  5	
hsCRP assay was performed using an immunoturbidimetric method  on a 6	
Modular P Analyzer (Roche Diagnostics, Vilvoorde, Belgium) with a 7	
quantitation limit of 0.5 mg/L. Maternal serum PAPP-A assay was performed 8	
on a IMMULITE 2000  immunoassay system (Siemens, Brussels, Belgium) 9	
with an enzyme-labeled chemiluminescent immunometric method. 10	
 11	
Statistical analysis 12	
The data were analyzed using data analysis and statistical software package 13	
Stata 13.1 (StataCorp, Texas, US). The outcome variable was the success of 14	
the expectant management, which was considered as a binary variable 15	
(success or failure), and the analysis was performed using logistic regression. 16	
The association between each variable and outcome was first assessed 17	
separately using a univariate analysis. The joint association on the outcome 18	
was assessed with a multivariate analysis. A backwards selection procedure 19	
was used to retain only the statistically significant variables in the final model 20	
removing non-significant variables, one at a time, until all remaining variables 21	
were significant.  22	
 For the categorical variables, data are displayed as odds of success in 23	
each category relative to the odds in a baseline category. For the continuous 24	
variables, the relative change in the odds of success for a one-unit increase in 25	
	 9	
the corresponding variable is presented. Variables that presented with 1	
skewed distributions were transformed using a logarithmic transformation 2	
before analysis. Results were considered statistically significant at P <0.05. 3	
 4	
Results 5	
The study group consisted of 83 women with a full set of data who opted for 6	
an expectant management including 64 (77.1%) women who had successful 7	
expectant management and 19 (22.9%) who required a surgical procedure. In 8	
five cases, the smoking status was not provided (n=3) or uncertain (n=2) due 9	
to passive smoking. Detailed information on the bleeding and pain at the time 10	
of the ultrasound examination was missing in two cases.  The average 11	
maternal age of the study group was 33.4 years with 32 women of advanced 12	
maternal age (AMA) (> 35 years old). A total of 58 women (70%) completed 13	
the follow-up in 2 weeks or less. 14	 	 A summary of the univariate analysis results is presented in table 1. 15	
This analysis indicated that, when examined individually, maternal age (p = 16	
0.01), progesterone (p = 0.03) and PAPP-A (p = 0.02) were all significantly 17	
associated with successful expectant management. Increased age was 18	
associated with an increased chance of success with the odds of success 19	
increased by around 75% for a 5-year increase in age.  Higher values of both 20	
progesterone and PAPP-A were associated with a reduced chance of 21	
successful management. A one-unit increase in progesterone on the log scale 22	
(equivalent to a 10-fold increase in progesterone) was associated with a 50% 23	
lower chance of successful expectant management. The study has an 80% 24	
power to detect a difference of 25% in outcome between groups, and over 25	
	 10	
90% to detect a difference of 30% between groups. 1	
	 The multivariate analysis (Table 2) indicated that both age (p  = 0.01) 2	
and progesterone (p  = 0.03) were significantly associated with successful 3	
management. After adjusting for these variables, there was no longer a 4	
significant effect of PAPP-A on the outcome. Older women were more likely to 5	
have successful management. A 5-year increase in age was associated with 6	
the odds of success increasing by 82%. Conversely higher levels of 7	
progesterone were associated with lower levels of success. A one-unit 8	
increase on the log scale (equivalent to a 10-fold increase in progesterone) 9	
was associated with a 50% drop in the odds of successful management. 10	
Progesterone and age were combined in a logistic regression model to 11	
predict the probability of successful management (p) using the following 12	
equation: 13	
p = ey / (1 + ey) where y = 0.356  +  0.078 age - 0.917 log progesterone 14	
 15	
Discussion  16	
The results of our study indicate that low maternal serum progesterone level 17	
is the strongest parameter associated with a successful spontaneous 18	
completion of miscarriage in cases of missed miscarriage. Combined with 19	
maternal age in a logistic regression model it may be used to determine the 20	
likelihood of successful expectant management. Our data also indicate that 21	
the role of maternal serum hsCRP and PAPP-A is limited and that routine 22	
measurement of the level of these proteins does not provide additional 23	
information for the management of missed miscarriage. 24	
	 11	
 The success of expectant management within two weeks is variable 1	
across observational studies (Casikar et al., 2010; Jurkovic et al., 2013; Knez 2	
et al., 2014). It is generally accepted that the likelihood of completion after two 3	
weeks is low and evacuation of the uterus should be offered. Completion 4	
rates are higher in incomplete miscarriages (80-96%) at two weeks with lower 5	
low complication rate than in missed miscarriage. In controlled trials of 6	
medical management, expectant management (placebo arm) was successful 7	
in 29 to 42% of women with missed miscarriage and 55% to 86% of women 8	
with incomplete miscarriage (Kovavisarach et al.,2002; Luise et al.,2002; 9	
Wood et al, 2002; Bagratee et al., 2004; Blohm et al., 2005; Lister et al., 10	
2005). The Royal College of Obstetricians and Gynaecologists( RCOG) 11	
evidenced-based guidelines on the care of women requesting induced 12	
abortion indicates that there is insufficient evidence to imply causality 13	
for pre-term birth and miscarriage following first trimester surgical 14	
abortion when the procedure is carried out in a high standard health 15	
care set up (RCOG 2011). However, several more recent systematic 16	
reviews have suggested that surgical management can be associated 17	
with increased risks of long-term complications such as preterm birth in 18	
subsequent pregnancies (Lemmers et al., 2016) and intrauterine 19	
adhesions (Hooker et al., 2015). 20	
 A meta-analysis of studies comparing expectant management with 21	
active management (medical or surgical) showed a higher rate of unplanned 22	
emergency interventions (NIH, 2012). In the present study, the completion 23	
rate was 78%, which is higher than in previous observational and cohort 24	
	 12	
studies. This may be due to the fact that our study included only cases of 1	
missed miscarriages. By contrast the majority of previous studies included 2	
both incomplete and missed miscarriage in their data analysis. The difference 3	
in outcome and success rates may also be due to different study populations 4	
and changes in maternal parameters over the last decade. In particular, our 5	
population includes a high number of women with AMA and in our study group 6	
the average maternal age was above the national average of 30.0 years 7	
reported recently for England and Wales (ONS, 2014). A history of previous 8	
miscarriage with different management approaches i.e. expectant, surgical or 9	
medical may also influence outcome in large series. 10	
 The diameter of retained products of conception as seen on ultrasound 11	
examination was assessed and found to be significantly different in women 12	
with successful and failed expectant management in a study that included 54 13	
women who were diagnosed either with an incomplete or missed miscarriage 14	
(Elson et al., 2005). Ultrasound parameters such as mean gestational sac 15	
diameter (MSD) and sac volume have not been routinely evaluated in the 16	
successful expectant management of missed miscarriage. In a study of 85 17	
women diagnosed with missed miscarriage, the mean diameter of the 18	
gestational sac at the initial ultrasound examination was found to be 19	
significantly smaller in women who successfully completed expectant 20	
management of missed miscarriage, compared with those who failed 21	
expectant management (Jurkovic et al, 1998). In this study, the cumulative 22	
success rates were 15%, 20% and 25% after one, two and > two weeks, 23	
respectively. In our study, no difference was observed when evaluating 24	
sonographic characteristics such as sac diameter and sac volume and 25	
	 13	
successful outcome of expectant management of missed miscarriage after 1	
two weeks. This could be explained by the maximum length of two weeks of 2	
follow-up offered to women who opted for expectant management in our study 3	
and the fact that our study only included women who opted for an expectant 4	
management.  5	
Maternal serum β-hCG and progesterone are the most commonly used 6	
serum markers in the assessment of pregnancy viability (Chetty et al., 2011). 7	
β-hCG levels are directly related to the amount of villous trophoblast whereas 8	
progesterone production in early pregnancy reflects the dynamics of the 9	
corpus luteum-trophoblast axis and the status of the trophoblastic tissue. It 10	
has previously been established that the likelihood of a spontaneous 11	
pregnancy failure declines as the maternal progesterone level rises in both 12	
intrauterine and extrauterine pregnancies (McCord et al. 1996; Verhaegen et 13	
al., 2012). A recent systematic review and diagnostic accuracy meta-analysis 14	
has confirmed that low serum progesterone is strongly associated with a 15	
failing pregnancy and can be used to rule out the possibility of a viable 16	
pregnancy (Pillai et al. 2016).  17	
Pregnancy associated plasma protein A (PAPP-A) is mainly produced 18	
by the villous trophoblast and its synthesis is up-regulated by progesterone 19	
during pregnancy (Wang et al., 2014). PAPP-A levels in maternal serum have 20	
been shown to be low in pregnancies with chromosomal abnormalities, like 21	
triploidy, trisomy 21, 18 and 13, and sex chromosome aneuploidy (Spencer et 22	
al., 2008, Suri et al., 2013). Low levels of PAPP-A have also been related to 23	
spontaneous miscarriage (Yaron et al., 2002). Our results confirm these 24	
	 14	
findings with women presenting with lower levels of progesterone and PAPP-1	
A having a higher rate of successful expectant management. 2	
 Recent studies have reported a possible role for the measure of 3	
maternal serum hsCRP in the first-trimester screening of pre-eclampsia 4	
(Kashanian et al., 2013), in predicting long-term cardiovascular risks in 5	
women who had hypertensive disorders late in pregnancy (Hermes et al., 6	
2013) and in the diagnosis of early-onset neonatal infection in cases of 7	
chorioamnionitis (Howman et al., 2012). We recently found that hsCRP levels 8	
do not predict the likelihood of miscarriage in women presenting with 9	
threatened miscarriage (Jauniaux et al., 2015). In the present study, hsCRP 10	
levels were not different between successful and unsuccessful subgroups, 11	
suggesting that this parameter does not contribute to the management of 12	
early pregnancy complications. 13	
 A mathematical model to predict successful expectant management of 14	
missed and incomplete miscarriages was validated in a recent prospective 15	
study (Casikar et al., 2013). The data were separated in 3 groups, missed 16	
miscarriage, anembryonic sac and incomplete miscarriage and the authors 17	
found that the most independent prognostic variables for their model are the 18	
type of miscarriage at primary scan, vaginal bleeding and maternal age. In our 19	
study, symptomatology at presentation was not recorded and therefore not 20	
included in the analysis. However, maternal age appears to be a common 21	
strong predictor probably due to the relationship between advanced maternal 22	
age (AMA) and aneuploidy rates. In addition, we found that routine 23	
biochemical markers can contribute to the management of missed 24	
	 15	
miscarriage with progesterone being the best biochemical marker to predict 1	
successful outcome.  2	
In conclusion, several novel biochemical markers such as angiogenic 3	
factors, macrophage inhibitory endoglin, macrophage inhibitory growth factor, 4	
endocannabinoids, cytokines, chemokines have been used to improve 5	
prediction of pregnancy outcome in women presenting with early pregnancy 6	
complications (Pillai et al. 2016). However, their cost and availability render 7	
them impossible to use in everyday clinical practice. By contrast, 8	
progesterone assays, are widely available in routine laboratories and used 9	
routinely in the management of ectopic pregnancy. In women diagnosed with 10	
a missed miscarriage, combining maternal age and progesterone level can 11	
aid clinicians and women in making informed decisions about treatment 12	
options available. Future research should focus on prospectively evaluating 13	
the mathematical model to identify at an early stage those women who are 14	
more likely to have unsuccessful management and thus avoiding the 15	
additional stress of requiring an emergency surgical procedure. 16	17	
	 16	
 1	
 2	
 3	
Acknowledgements: The authors wish to thanks Mr Paul Bassett (UCLH) for 4	
the help with the statistical analysis and the department of clinical chemistry at 5	
Hopital Erasme, Université Libre de Bruxelles (ULB) for the laboratory 6	
support. 7	
 8	
Conflict of interest: None to declare. 9	
 10	
 11	
 12	13	
	 17	
1.  REFERENCES 1	
 2	
Bagratee JS, Khullar V, Regan L, Moodley J, Kagoro H. A randomized 3	
 controlled trial comparing medical and expectant management of first 4	
 trimester miscarriage. Hum Reprod 2004;2:266-271. 5	
Blohm F, Friden BE, Milsom I, Platz-Christensen JJ, Nielsen S. A randomised 6	
 double blind trial comparing misoprostol or placebo in the management 7	
 of early miscarriage. BJOG 2005;8:1090-1095. 8	
Casikar I, Bignardi T, Riemke J, Alhamdan D, Condous G. Expectant 9	
 management of spontaneous first-trimester miscarriage: prospective 10	
 validation of the '2-week rule'. Ultrasound Obstet Gynecol 2010;35:223-11	
 227. 12	
Casikar I, Lu C, Reid S, Condous G. Prediction of successful expectant 13	
 management of first trimester miscarriage: development and validation 14	
 of a new mathematical model. Aust N Z J Obstet Gynaecol 2013;53:58-15	
 63. 16	
Chetty M, Sawyer E, Dew T, Chapman AJ, Elson J. The use of novel 17	
 biochemical markers in predicting spontaneously resolving 18	
 'pregnancies of unknown location'. Hum Reprod 2011;26:1318-1323. 19	
Elson J, Tailor A, Salim R, Hillaby K, Dew T, Jurkovic D. Expectant 20	
 management of miscarriage—prediction of outcome using ultrasound 21	
 and novel biochemical markers. Hum Reprod 2005;20:2330-2333. 22	
Hermes W, Franx A, van Pampus MG, Bloemenkamp KW, Bots ML, van der 23	
 Post JA, Porath M, Ponjee GA, Tamsma JT, Mol BW, de Groot CJ. 24	
 Cardiovascular risk factors in women who had hypertensive disorders 25	
 late in pregnancy: a cohort study. Am J Obstet Gynecol 26	
	 18	
 2013;208:474.e1-8. 1	
Hooker AB, Aydin H, Brölmann HA, Huirne JA. Long-term complications and 2	
 reproductive outcome after the management of retained products of 3	
 conception: a systematic review. Fertil Steril 2016;105:156-64.e-2. 4	
Howman RA, Charles AK, Jacques A, Doherty DA, Simmer K, Strunk T, 5	
 Richmond PC, Cole CH, Burgner DP. Inflammatory and haematological 6	
 markers in the maternal, umbilical cord and infant circulation in 7	
 histological chorioamnionitis. PLoS One 2012;7:e51836. 8	
Jauniaux E, Gulbis B, Jamil A, Jurkovic D. Evaluation of the role of maternal 9	
 serum high-sensitivity C-reactive protein in predicting early pregnancy 10	
 failure. Reprod Biomed Online 2015;30:268-274. 11	
Jurkovic D, Ross JA, Nicolaides KH. Expectant management of missed 12	
 miscarriage. Br J Obstet Gynaecol 1998;105:670-671. 13	
Jurkovic D, Overton C, Bender-Atik R. Diagnosis and management of first 14	
 trimester miscarriage. BMJ 2013;346:f3676. 15	
Kalogeropoulos AP, Tang WH, Hsu A, Felker GM, Hernandez AF, Troughton 16	
 RW, Voors AA, Anker SD, Metra M, McMurray JJ, Massie BM, 17	
Ezekowitz JA, Califf RM, O'Connor CM, Starling RC, Butler J. High- sensitivity 18	
 C-reactive protein in acute heart failure: insights from the ASCEND-HF 19	
 trial. J Card Fail 2014;20:319-326. 20	
Kashanian M, Aghbali F, Mahali N. Evaluation of the diagnostic value of the 21	
 first-trimester maternal serum high-sensitivity C-reactive protein level 22	
 for prediction of pre-eclampsia. J Obstet Gynaecol Res 2013;39:1549-23	
 1554. 24	
	 19	
Knez J, Day A, Jurkovic D. Ultrasound imaging in the management of 1	
 bleeding and pain in early pregnancy. Best Pract Res Clin Obstet 2	
 Gynaecol 2014;28:621-36.  3	
Kovavisarach E, Sathapanachai U. Intravaginal 400 microg misoprostol for 4	
 pregnancy termination in cases of blighted ovum: a randomised 5	
 controlled trial. Aust N Z J Obstet Gynaecol 2002;2:161-163. 6	
Lemmers M, Verschoor MA, Hooker AB, Opmeer BC, Limpens J, Huirne JA, 7	
 Ankum WM, Mol BW. Dilatation and curettage increases the risk of 8	
 subsequent preterm birth: a systematic review and meta-analysis. Hum 9	
 Reprod 2016;31:34-45. 10	
Lister MS, Shaffer LE, Bell JG, Lutter KQ, Moorma KH. Randomized, double-11	
 blind, placebo-controlled trial of vaginal misoprostol for management of 12	
 early pregnancy failures. Am J Obstet Gynecol 2005;4:1338-1343. 13	
Luise C, Jermy K, May C, Costello G, Collins WP, Bourne T. Outcome of  14	
  expectant management of spontaneous first trimester miscarriage:  15	
  observational study. BMJ 2002;324:873-875. 16	
McCord ML, Muram D, Buster JE, Arheart KL, Stovall TG, Carson SA. Single 17	
 serum progesterone as a screen for ectopic pregnancy: exchanging 18	
 specificity and sensitivity to obtain optimal test performance. Fertil 19	
 Steril 1996;66:513-516. 20	
Nanda K, Lopez LM, Grimes DA, Peloggia A, Nanda G. Expectant care 21	
 versus surgical treatment for miscarriage. Cochrane Database Syst 22	
 Rev 2012;3:CD003518.  23	
National Institute for Health and Care Excellence (NICE). Ectopic pregnancy 24	
	 20	
 and  miscarriage: diagnosis and initial management in early pregnancy 1	
 of ectopic pregnancy and miscarriage. Guideline CG154. 2012. 2	
 http://publications.nice.org.uk/ectopic-pregnancy-and-miscarriage-3	
 cg154. 4	
Nybo Andersen AM, Wohlfahrt J, Christens P, Olsen J, Melbye M. Maternal 5	
 age and fetal loss: population based register linkage study. BMJ 6	
 2000;320:1708-12. 7	
Office for National Statistics. Births in England and Wales 2013. 8	
www.ons.gov.uk, 2014. 9	
Pillai RN, Konje JC, Tincello DG, Potdar N. Role of serum biomarkers in the 10	
prediction of outcome in women with threatened miscarriage: a 11	
systematic review and diagnostic accuracy meta-analysis Hum Repro 12	
Update 2016;22:228-293. 13	
Royal College of Obstetricians and Gynaecologists Evidence-based clinical 14	
No 7: The care of women requesting induced abortion. 15	
www.rcog.org.uk/womens-health/clinical.../care-women-16	
requesting-induced-abortion, 2011. 17	
Sairam S, Khare M, Michalidis G, Thilaganathan B. The role of ultrasound in 18	
  the expectant management of early pregnancy loss. Ultrasound in  19	
  Obstetrics Gynecology 2001;17:506-9. 20	
Shankar M, Economides DL, Sabin CA, Tan B, Kadir RA. Outpatient medical 21	
 management of missed miscarriage using misoprostol. J Obstet 22	
 Gynaecol 2007;27:283-286. 23	
	 21	
Spencer K, Cowans NJ, Avgidou K, Molina F, Nicolaides KH. First-trimester 1	
 biochemical markers of aneuploidy and the prediction of small-for-2	
 gestational age fetuses. Ultrasound Obstet Gynecol 2008;31:15–19. 3	
Suri S, Muttukrishna S, Jauniaux E. 2D-Ultrasound and endocrinologic 4	
 evaluation of placentation in early pregnancy and its relationship to 5	
 fetal birthweight in normal pregnancies and pre-eclampsia. Placenta 6	
 2013;34:745-750.  7	
Verhaegen J, Gallos ID, van Mello NM, Abdel-Aziz M, Takwoingi Y, Harb H, 8	
 Deeks JJ, Mol BW, Coomarasamy A. Accuracy of single progesterone 9	
 test to predict early pregnancy outcome in women with pain or 10	
 bleeding: meta-analysis of cohort studies. BMJ 2012;345:e6077. 11	
Wang J, Liu S, Qin HM, Zhao Y, Wang XQ, Yan Q. Pregnancy-associated 12	
 plasma protein A up-regulated by progesterone promotes adhesion 13	
 and proliferation of trophoblastic cells. Int J Clin Exp Pathol 14	
 2014;7:1427-1437.  15	
Wells G, Bleicher K, Han X, McShane M, Chan YF, Bartlett A, White C, Lau 16	
 SM. Maternal Diabetes, Large-for-Gestational-Age Births, and First 17	
 Trimester Pregnancy-Associated Plasma Protein-A. J Clin Endocrinol 18	
 Metab 2015;100:2372-2379. 19	
Wood SL, Brain PH. Medical management of missed abortion: a randomized 20	
 clinical trial. Obstet Gynecol 2002;4:563-566. 21	
Yaron Y, Ochshorn Y, Heifetz S, Lehavi O, Sapir Y, Orr-Urtreger A. First 22	
 trimester maternal serum free human chorionic gonadotropin as a 23	
 predictor of adverse pregnancy outcome. Fetal Diagn Ther 24	
 2002;17:352- 356. 25	
	 22	
Yliniemi A, Nurkkala MM, Kopman S, Korpimaki T, Kouru H, Ryynanen M, 1	
 Marttala J. First trimester placental retinol-binding protein 4 (RBP4) and 2	
 pregnancy-associated placental protein A (PAPP-A) in the prediction of 3	
 early-onset severe pre-eclampsia. Metabolism 2015;64:521-526. 4	
 5	
 6	
 7	8	
	 23	
Table 1: Results of the univariate analysis of the different variables 1	
investigated in successful expectant management (n= 64). 2	
 3	
Variable Category Success  
Number (%) 
Odds Ratio  
(95% CI) 
P-value 
     
Age (*) - - 1.77 (1.13, 2.76) 0.01 
     
Ethnicity Caucasian 37/52 (71%)   1 NS 
 South Asian 13/15 (87%) 2.64 (0.53, 13.1)  
 Afro-
Caribbean 
6/7 (86%) 2.43 (0.27, 22.0)  
 Other 8/9 (89%) 2.43 (0.27, 22.0)  
     
BMI (*) - - 1.07 (0.62, 1.84) NS 
     
Smokera No 56/71 (79%)   1 NS 
 Yes 5/7 (71%) 0.79 (0.14, 4.43)  
     
Parity 0 34/47 (72%)   1 NS 
 1 14/18 (78%) 1.33 (0.37, 4.82)  
 2+ 16/18 (89%) 3.06 (0.62, 15.2)  
     
Pain None 
Mild/Moderate 
38/52 (73%) 
24/29 (83%) 
1 
1.77 (0.56, 5.54) 
NS 
 
     
Bleedinga None/Mild 
Moderate 
Heavy 
38/50 (76%) 
17/22 (77%) 
7/9 (78%) 
1 
1.07 (0.33, 3.52) 
1.11 (0.20, 6.05) 
NS 
     
Sac diameter (**) - - 0.81 (0.50, 1.31) NS 
     
Sac volume (†) - - 0.80 (0.49, 1.31) NS 
      
Gest. age (wks) - - 0.99 (0.72, 1.34) NS 
     
βhCG (†) - - 0.73 (0.49, 1.08) NS 
     
Progesterone (†) - - 0.46 (0.23, 0.91) 0.03 
     
CRP (†) - - 1.14 (0.70, 1.87) NS 
     
PAPP-A (†) - - 0.62 (0.41, 0.94) 0.02 
     
(*)   Odds ratios given for a 5-unit increase in predictor variable 4	
(**) Odds ratios given for a 10-unit increase in predictor variable 5	
(†)   Variable analysed on log scale 6	
a Missing data in some cases. 7	
 8	9	
	 24	
Table 2: Significant results of multivariate analysis in successful expectant 1	
management (n=64). 2	
 3	
Variable Odds Ratio (95% CI) P-value 
   
Age (*) 1.82 (1.14, 2.91) 0.01 
Progesterone (†) 0.44 (0.21, 0.90) 0.03 
   
(*) Odds ratios given for a 5-unit increase in predictor variable 4	
(†) Variable analysed on log scale 5	
 6	
 7	
